A recent preclinical study showed that the combination of a Menin inhibitor (VTP-50469, an analog of Revumenib) and Selutenib (a MEK 1–2 inhibitor) exerted a synergistic antitumor effect in vitro and in PDX models of KMT2A-rearranged AML cells bearing RAS pathway mutations [106]. The gene discussed is MEN1; the disease is acute myeloid leukemia.